Skip to content
‹ Back to IndustriesSciences

Why Microbes Can Be the Best Solution for Waterfloods, Saltwater Disposals and More

Bill Lantz worked for decades in the oil fields working with microbes. He saw just about every issue that can crop up, with companies often turning to chemicals to try and deal with waterflood, saltwater disposals, paraffin and more. Lantz founded JGL Solutions in 2006 after gaining experience utilizing a better solution – microbes….

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Daniel Litwin · · Bill Lantz PodcastMicrobesMicrobes in the OilfieldMicrobial Solutions
Share

Key takeaways

01

Bill Lantz worked for decades in the oil fields working with microbes.

02

He saw just about every issue that can crop up, with companies often turning to chemicals to try and deal with waterflood, saltwater disposals, paraffin and more.

03

Lantz founded JGL Solutions in 2006 after gaining experience utilizing a better solution – microbes….

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Bill Lantz worked for decades in the oil fields working with microbes.

He saw just about every issue that can crop up, with companies often turning to chemicals to try and deal with waterflood, saltwater disposals, paraffin and more. Lantz founded JGL Solutions in 2006 after gaining experience utilizing a better solution – microbes.

“They have a lot of (issues) that mostly they use chemicals to solve, and, once you know what these are and know there are microbes that actually do the same things chemicals do, only better, and do more than chemicals do, it’s really kind of amazing,” he said. “Being able to apply them at critical spots in a production spots and knowing what you’re doing … is a lot of it.”

The microbes provide not only a more effective solution but also one that is better for the environment, something many big energy companies love to hear as sustainability becomes more of a real focus and less of simply a buzzword.

“Now, you’re getting companies more worried about what they might actually be doing to the environment, so products like ours are perfect for that,” Lantz said. “What they’re finding out with our microbes is they’re more effective. Not only is it great for the environment, it’s much more effective than what they’re using, anyway.”

That makes looking into microbes as a solution for the issues that can occur in oil fields a smart play, and with Lantz and his team having decades of experience in the industry, JGL Solutions should be the first call.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

Daniel Litwin
Daniel LitwinEditor, B2B Media, MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

AI shows up in all five tracks at ISPE's 2026 Annual Meeting

AI shows up in all five tracks at ISPE's 2026 Annual Meeting

ISPE's 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC explaining why AI appears across every track rather than in a standalone one. Deloitte's December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE's 2026 Annual Meeting has no dedicated AI track; program chairs expect AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte's December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own financial outlook but only 41% optimistic about the global economy, the mood the program is built for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation with tagged models enables tracking of tumor growth in the organ where it naturally occurs, supporting clinically relevant assessment of therapies delivered in that setting.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Daniel Litwin
Daniel Litwin

Editor, B2B Media

MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512